Aus coViki
Wechseln zu: Navigation, Suche
  • GET 2020. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed Extract
  • GET 2020. Anti-TNF-alpha Agents in Inflammatory Bowel Disease and Course of COVID-19. Extract
  • GET 2020. Potential inhibition of COVID-19-driven pneumonia by immunosuppressive therapy and anti-TNFalpha antibodies: a case report. Extract
  • GET 2020. TNFalpha inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis. Extract
  • GET 2020. Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds. Extract
  • GET 2020. TNFalpha-antagonist use and mucosal inflammation are associated with increased intestinal expression of SARS-CoV-2 host protease TMPRSS2 in patients with inflammatory bowel disease. Extract


  • GET 2020. COVID-19: Pentoxifylline as a potential adjuvant treatment. Extract
  • GET 2020. Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy? Extract
  • GET 2020. Pentoxifylline and complicated COVID-19: A pathophysiologically based treatment proposal. Extract
  • GET 2020. Repositioning of pentoxifylline as an immunomodulator and regulator of the renin-angiotensin system in the treatment of COVID-19. Extract
Meine Werkzeuge